Structure, function and amyloidogenic propensity of apolipoprotein A-I

References

• Westermark P, Benson M D, Buxbaum J N, Cohen A S, Frangione B, Ikeda S, Masters C L, Merlini G, Saraiva M J, Sipe J D. Amyloid: Toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid J Protein Folding Disord 2005; 12: 1–4
   PubMed Web of Science ®Google Scholar
• Gallo G, Wisniewski T, Choimiura N H, Ghiso J, Frangione B. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994; 145: 526–530
   PubMed Web of Science ®Google Scholar
• Hatters D M, Lawrence L J, Howlett G J. Sub-micellar phospholipid accelerates amyloid formation by apolipoprotein C-II. FEBS Lett 2001; 494: 220–224
   PubMed Web of Science ®Google Scholar
• Rocken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002; 440: 111–122
   PubMed Web of Science ®Google Scholar
• Benson M D. Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid J Protein Folding Disord 2005; 12: 75–87
   PubMed Web of Science ®Google Scholar
• Gregorini G, Izzi C, Obici L, Tardanico R, Rocken C, Viola B F, Capistrano M, Donadei S, Biasi L, Scalvini T, Merlini G, Scolari F. Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol 2005; 16: 3680–3686
   PubMed Web of Science ®Google Scholar
• Obici L, Bellotti V, Mangione P, Stoppini M, Arbustini E, Verga L, Zorzoli I, Anesi E, Zanotti G, Campana C, Vigano M, Merlini G. The new apolipoprotein A-I variant Leu174Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. Am J Pathol 1999; 155: 695–702
   PubMed Web of Science ®Google Scholar
• Hamidi L Asl, Liepnieks J J, Hamidi K Asl, Uemichi T, Moulin G, Desjoyaux E, Loire R, Delpech M, Grateau G, Benson M D. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1. Am J Pathol 1999; 154: 221–227
   PubMed Web of Science ®Google Scholar
• de Sousa M M, Vital C, Ostler D, Fernandes R, Pouget-Abadie J, Carles D, Saraiva M J. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol 2000; 156: 1911–1917
   PubMed Web of Science ®Google Scholar
• Schrepferman C G, Lester D R, Sandlow J I. Testicular amyloid deposition as a cause of secondary azoospermia. Urology 2000; 55: 145–146
   PubMedGoogle Scholar
• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. New Engl J Med 2003; 349: 583–596
   PubMed Web of Science ®Google Scholar
• Elimova E, Kisilevsky R, Szarek W A, Ancsin J B. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J 2004; 18: 1749–1751
   PubMed Web of Science ®Google Scholar
• Fielding C J, Fielding P E. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211–228
   PubMed Web of Science ®Google Scholar
• Ikewaki K, Rader D J, Schaefer J R, Fairwell T, Zech L A, Brewer H B, Jr. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res 1993; 34: 2207–2215
   PubMed Web of Science ®Google Scholar
• Pagani F, Sidoli A, Giudici G A, Barenghi L, Vergani C, Baralle F E. Human apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia. J Lipid Res 1990; 31: 1371–1377
   PubMed Web of Science ®Google Scholar
• Barre D E, Guerra R, Verstraete R, Wang Z, Grundy S M, Cohen J C. Genetic analysis of a polymorphism in the human apolipoprotein A-I gene promoter: effect on plasma HDL-cholesterol levels. J Lipid Res 1994; 35: 1292–1296
   PubMed Web of Science ®Google Scholar
• Brinton E A. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein AI and lowers hepatic lipase activity without lowering catabolic rate. Arterioscler Thromb Vasc Biol 1996; 16: 431–440
   PubMed Web of Science ®Google Scholar
• Zhang X, Jiao J J, Bhavnani B, Tam S P. Regulation of human apolipoprotein A-I gene expression by equine estrogens. J Lipid Res 2001; 42: 1789–1880
   PubMed Web of Science ®Google Scholar
• Harnish D C, Evans M J, Scichitano M S, Bhat R A, Karathanasis S K. Estrogen regulation of the apolipoprotein Al promoter through transcription factor sharing. J Biol Chem 1998; 273: 9270–9278
   PubMed Web of Science ®Google Scholar
• Wehmeier K, Beers A, Haas M J, Wong N C, Steinmeyer A, Zugel U, Mooradian A D. Inhibition of apolipoprotein AI gene expression by 1,25-dihydroxyvitamin D3. Biochim Biophys Acta 2005; 1737: 16–26
   PubMed Web of Science ®Google Scholar
• Mooradian A D, Haas M J, Wadud K. Ascorbic acid and alpha-tocopherol down-regulate apolipoprotein A-I gene expression in HepG2 and Caco-2 cell lines. Metabolism 2006; 55: 159–167
   PubMed Web of Science ®Google Scholar
• Law S W, Brewer H B, Jr. Nucleotide sequence and the encoded amino acids of human apolipoprotein A-I mRNA. Proc Natl Acad Sci USA 1984; 81: 66–70
   PubMed Web of Science ®Google Scholar
• Scanu A M, Byrne R E, Edelstein C. Proteolytic events affecting plasma apolipoproteins at the co- and post-translational levels and after maturation. J Lipid Res 1984; 25: 1593–1602
   PubMed Web of Science ®Google Scholar
• Batal R, Tremblay M, Krimbou L, Mamer O, Davignon J, Genest J, Jr, Cohn J S. Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I. Arterioscler Thromb Vasc Biol 1998; 18: 655–664
   PubMed Web of Science ®Google Scholar
• Chisholm J W, Burleson E R, Shelness G S, Parks J S. ApoA-I secretion from HepG2 cells: evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL. J Lipid Res 2002; 43: 36–44
   PubMed Web of Science ®Google Scholar
• Kiss R S, McManus D C, Franklin V, Tan W L, McKenzie A, Chimini G, Marcel Y L. The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and –independent pathways. J Biol Chem 2003; 278: 10119–10127
   PubMed Web of Science ®Google Scholar
• Hamilton R L, Moorehouse A, Havel R J. Isolation and properties of nascent lipoproteins from highly purified rat hepatocytic Golgi fractions. J Lipid Res 1991; 32: 529–543
   PubMed Web of Science ®Google Scholar
• Tsujita M, Wu C A, Abe-Dohmae S, Usui S, Okazaki M, Yokoyama S. On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway. J Lipid Res 2005; 46: 154–162
   PubMed Web of Science ®Google Scholar
• Schaefer E J, Jenkins L L, Brewer H B, Jr. Human chylomicron apolipoprotein metabolism. Biochem Biophys Res Commun 1978; 80: 405–412
   PubMed Web of Science ®Google Scholar
• Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000; 1529: 245–256
   PubMed Web of Science ®Google Scholar
• Sorci-Thomas M G, Thomas M J. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med 2002; 12: 121–128
   PubMed Web of Science ®Google Scholar
• de Beer M C, Durbin D M, Cai L, Jonas A, de Beer F C, van der Westhuyzen D R. Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI. J Lipid Res 2001; 42: 309–313
   PubMed Web of Science ®Google Scholar
• Trigatti B L, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 1732–1738
   PubMed Web of Science ®Google Scholar
• Rye K A, Barter P J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004; 24: 421–428
   PubMed Web of Science ®Google Scholar
• Lawn R M, Wade D P, Couse T L, Wilcox J N. Localization of human ATP-binding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler Thromb Vasc Biol 2001; 21: 378–385
   PubMed Web of Science ®Google Scholar
• Eckhardt E R, Cai L, Sun B, Webb N R, van der Westhuyzen D R. High density lipoprotein uptake by scavenger receptor SR-BII. J Biol Chem 2004; 279: 14372–14381
   PubMedGoogle Scholar
• Martinez L O, Jacquet S, Esteve J P, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker J E, Terce F, Collet X, Perret B, Barbaras R. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003; 421: 75–79
   PubMed Web of Science ®Google Scholar
• Glass C K, Pittman R C, Keller G A, Steinberg D. Tissue sites of degradation of apolipoprotein A-I in the rat. J Biol Chem 1983; 258: 7161–7167
   PubMed Web of Science ®Google Scholar
• Moestrup S K, Kozyraki R. Cubilin, a high-density lipoprotein receptor. Curr Opin Lipidol 2000; 11: 133–140
   PubMed Web of Science ®Google Scholar
• Kozyraki R, Fyfe J, Kristiansen M, Gerdes C, Jacobsen C, Cui S, Christensen E I, Aminoff M, de la Chapelle A, Krahe R, Verroust P J, Moestrup S K. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med 1999; 5: 656–661
   PubMed Web of Science ®Google Scholar
• Braschi S, Neville T A, Vohl M C, Sparks D L. Apolipoprotein A-I charge and conformation regulate the clearance of reconstituted high density lipoprotein in vivo. J Lipid Res 1999; 40: 522–532
   PubMed Web of Science ®Google Scholar
• Calabresi L, Meng Q H, Castro G R, Marcel Y L. Apolipoprotein A-I conformation in discoidal particles: evidence for alternate structures. Biochemistry 1993; 32: 6477–6484
   PubMed Web of Science ®Google Scholar
• Segrest J P, De Loof H, Dohlman J G, Brouillette C G, Anantharamaiah G M. Amphipathic helix motif: classes and properties. Proteins 1990; 8: 103–117
   PubMed Web of Science ®Google Scholar
• Borhani D W, Rogers D P, Engler J A, Brouillette C G. Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc Natl Acad Sci USA 1997; 94: 12291–12296
   PubMed Web of Science ®Google Scholar
• Ajees A A, Anantharamaiah G M, Mishra V K, Hussain M M, Murthy H M. Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA 2006; 103: 2126–2131
   PubMed Web of Science ®Google Scholar
• Wang G, Sparrow J T, Cushley R J. The helix-hinge-helix structural motif in human apolipoprotein A-I determined by NMR spectroscopy. Biochemistry 1997; 36: 13657–13666
   PubMed Web of Science ®Google Scholar
• Bhat S, Sorci-Thomas M G, Alexander E T, Samuel M P, Thomas M J. Intermolecular contact between globular N-terminal fold and C-terminal domain of ApoA-I stabilizes its lipid-bound conformation: studies employing chemical cross-linking and mass spectrometry. J Biol Chem 2005; 280: 33015–33025
   PubMed Web of Science ®Google Scholar
• Brouillette C G, Anantharamaiah G M, Engler J A, Borhani D W. Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta 2001; 1531: 4–46
   PubMed Web of Science ®Google Scholar
• Gross E, Peng D Q, Hazen S L, Smith J D. A novel folding intermediate state for apolipoprotein A-I: role of the amino and carboxy termini. Biophys J 2006; 90: 1362–1370
   PubMed Web of Science ®Google Scholar
• Gursky O, Atkinson D. Thermal unfolding of human high-density apolipoprotein A-1: implications for a lipid-free molten globular state. Proc Natl Acad Sci USA 1996; 93: 2991–2995
   PubMed Web of Science ®Google Scholar
• Marcel Y L, Kiss R S. Structure-function relationships of apolipoprotein A-I: a flexible protein with dynamic lipid associations. Curr Opin Lipidol 2003; 14: 151–157
   PubMed Web of Science ®Google Scholar
• Scott B R, McManus D C, Franklin V, McKenzie A G, Neville T, Sparks D L, Marcel Y L. The N-terminal globular domain and the first class A amphipathic helix of apolipoprotein A-I are important for lecithin:cholesterol acyltransferase activation and the maturation of high density lipoprotein in vivo. J Biol Chem 2001; 276: 48716–48724
   PubMed Web of Science ®Google Scholar
• Burgess J W, Frank P G, Franklin V, Liang P, McManus D C, Desforges M, Rassart E, Marcel Y L. Deletion of the C-terminal domain of apolipoprotein A-I impairs cell surface binding and lipid efflux in macrophage. Biochemistry 1999; 38: 14525–14533
   Web of Science ®Google Scholar
• Van den B Berg, Wain R, Dobson C M, Ellis R J. Macromolecular crowding perturbs protein refolding kinetics: implications for folding inside the cell. EMBO J 2000; 19: 3870–3875
   PubMed Web of Science ®Google Scholar
• Bhat S, Zabalawi M, Willingham M C, Shelness G S, Thomas M J, Sorci-Thomas M G. Quality control in the apoA-I secretory pathway: deletion of apoA-I helix 6 leads to the formation of cytosolic phospholipid inclusions. J Lipid Res 2004; 45: 1207–1220
   PubMed Web of Science ®Google Scholar
• von Eckardstein A, Funke H, walter M, Altland K, Benninghoven A, Assman G. Structural analysis of human apolipoproteinA-I variants. J Biol Chem 1990; 265: 8610–8617
   PubMed Web of Science ®Google Scholar
• Frank P G, Marcel Y L. Apolipoprotein A-I: structure-function relatioship. J Lipid Res 2000; 41: 853–872
   PubMed Web of Science ®Google Scholar
• Wiesgraber K H, Bersot T P, Mahley R W, Franceschini G, Sirtori C R. A-I Milano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoprotein. J Clin Invest 1980; 66: 901–907
   PubMed Web of Science ®Google Scholar
• Sorci-Thomas M G, Thomas M, Curtiss L, Landrum M. Single repeat deletion in apoA-I blocks cholesterol esterification and results in rapid catabolism of Δ6 and wild-type apoA-I in transgenic mice. J Biol Chem 2000; 275: 12156–12163
   PubMed Web of Science ®Google Scholar
• Nichols W C, Dwulet F E, Liepnieks J, Benson M D. Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. Biochem Biophys Res Commun 1988; 156: 762–768
   PubMed Web of Science ®Google Scholar
• Soutar A K, Hawkins P N, Vigushin D M, Tennent G A, Booth S E, Hutton T, Nguyen O, Totty N F, Feest T G, Hsuan J J, Pepys M. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci USA 1992; 89: 7389–7393
   PubMed Web of Science ®Google Scholar
• Booth D R, Tan S Y, Booth S E, Hsuan J J, Totty N F, Nguyen O, Hutton T, Vigushin D M, Tennent G A, Hutchinson W L, Thompson N, Soutar A K, Hawkins P N, Pepys M. A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM 1995; 88: 695–702
   PubMed Web of Science ®Google Scholar
• Booth D R, Tan S Y, Booth S E, Tennent G A, Hutchinson W L, Hsuan J J, Totty N F, Truong O, Soutar A K, Hawkins P N, Bruguera M, Caballeria J, Sole M, Campistol J M, Pepys M B. Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. J Clin Invest 1996; 97: 2714–2721
   PubMed Web of Science ®Google Scholar
• Persey M R, Booth D R, Booth S E, van Zyl-Smit R, Adams B K, Fattaar A B, Tennent G A, Hawkins P N, Pepys M B. Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int 1998; 53: 276–281
   PubMed Web of Science ®Google Scholar
• Pepys M B, Tennent G A, Booth D R, Bellotti V, Lovat L B, Tan S Y, Persey M R, Hutchinson W L, Booth S E, Madhoo S, Soutar A K, Hawkins P N, Van Zyl-Smit R, Campistol J M, Fraser P E, Radford S E, Robinson C V, Sunde M, Serpell L C, Blake C C. Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy. Ciba Found Symp 1996; 199: 73–81
   PubMedGoogle Scholar
• Obici L, Palladini G, Giorgetti S, Bellotti V, Gregorini G, Arbustini E, Verga L, Marciano S, Donadei S, Perfetti V, Calabresi L, Bergonzi C, Scolari F, Merlini G. Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology 2004; 126: 1416–1422
   PubMed Web of Science ®Google Scholar
• Coriu D, Dispenzieri A, Stevens F J, Murphy C L, Wang S, Weiss D T, Solomon A. Hepatic amyloidosis resulting from deposition of the apolipoprotein A-I variant Leu75Pro. Amyloid J Protein Folding Disord 2003; 10: 215–223
   PubMed Web of Science ®Google Scholar
• Murphy C L, Wang S, Weaver K, Gertz M A, Weiss D T, Solomon A. Renal apolipoprotein A-I amyloidosis associated with a novel mutant Leu64Pro. Am J Kidney Dis 2004; 44: 1103–1109
   PubMed Web of Science ®Google Scholar
• Hamidi K Asl, Liepnieks J J, Nakamura M, Parker F, Benson M D. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun 1999; 257: 584–588
   PubMed Web of Science ®Google Scholar
• Lachmann H J, Booth D R, Booth S E, Bybee A, Gilbertson J A, Gillmore J D, Pepys M B, Hawkins P N. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. New Engl J Med 2002; 346: 1786–1791
   PubMed Web of Science ®Google Scholar
• Chou P Y, Fasman G D. Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol 1978; 47: 145–148
   Google Scholar
• Mangione P, Sunde M, Giorgetti S, Stoppini M, Esposito G, Gianelli L, Obici L, Asti L, Andreola A, Viglino P, Merlini G, Bellotti V. Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. Protein Sci 2001; 10: 187–199
   PubMed Web of Science ®Google Scholar
• Relini A, Rolandi R, Bolognesi M, Aboudan M, Merlini G, Bellotti V, Gliozzi A. Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: an atomic force microscopy study. Biochim Biophys Acta 2004; 1690: 33–41
   PubMed Web of Science ®Google Scholar
• Serpell L C, Sunde M, Benson M D, Tennent G A, Pepys M B, Fraser P E. The protofilament substructure of amyloid fibrils. J Mol Biol 2000; 300: 1033–1039
   PubMed Web of Science ®Google Scholar
• Ji Y, Jonas A. Properties of an N-terminal proteolytic fragment of apolipoprotein AI in solution and in reconstituted high density lipoproteins. J Biol Chem 1995; 270: 11290–11297
   PubMed Web of Science ®Google Scholar
• Roberts L M, Ray M J, Shih T W, Hayden H, Reader M M, Brouillette C G. Structural analysis of apolipoprotein A-I: limited proteolysis of methionine-reduced and oxidized lipid-free and lipid-bound human apo A-I. Biochemistry 1997; 36: 7615–7624
   PubMed Web of Science ®Google Scholar
• Rogers D P, Roberts L M, Lebowitz J, Engler J A, Brouillette C G. Structural analysis of apolipoprotein A-I: effects of amino- and carboxy-terminal deletions on the lipid-free structure. Biochemistry 1998; 37: 945–955
   PubMed Web of Science ®Google Scholar
• Eberini I, Calabresi L, Wait R, Tedeschi G, Pirillo A, Puglisi L, Sirtori C R, Gianazza E. Macrophage metalloproteinases degrade high-density lipoprotein-associated apolipoprotein A-I at both the N- and C-termini. Biochem J 2002; 362: 627–634
   PubMed Web of Science ®Google Scholar
• McManus D C, Scott B R, Franklin V, Sparks D L, Marcel Y L. Proteolytic degradation and impaired secretion of an apolipoprotein A-I mutant associated with dominantly inherited hypoalphalipoproteinemia. J Biol Chem 2001; 276: 21292–21302
   PubMed Web of Science ®Google Scholar
• Miettinen H E, Jauhiainen M, Gylling H, Ehnholm S, Palomaki A, Miettinen T A, Kontula K. Apolipoprotein A-IFIN (Leu159→Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts. Arterioscler Thromb Vasc Biol 1997; 17: 3021–3032
   PubMed Web of Science ®Google Scholar
• Bellotti V, Obici L, Kisilevsky R, Merlini G. Anatomic and clinical clues to in vivo mechanisms of amyloidogenesis. Amyloid proteins. The beta sheet conformation and disease, J D Sipe. Wiley-VCH, Weinheim 2005; 2–48
   Google Scholar
• Andreola A, Bellotti V, Giorgetti S, Mangione P, Obici L, Stoppini M, Torres J, Monzani E, Merlini G, Sunde M. Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein A-I. J Biol Chem 2003; 278: 2444–2451
   PubMed Web of Science ®Google Scholar
• Westermark P, Mucchiano G, Marthin T, Johnson K H, Sletten K. Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Am J Pathol 1995; 147: 1186–1192
   PubMed Web of Science ®Google Scholar
• Mucchiano G I, Haggqvist B, Sletten K, Westermark P. Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 2001; 193: 270–275
   PubMed Web of Science ®Google Scholar
• Amarzguioui M, Mucchiano G, Haggqvist B, Westermark P, Kavlie A, Sletten K, Prydz H. Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation. Biochem Biophys Res Commun 1998; 242: 534–539
   PubMed Web of Science ®Google Scholar
• Mucchiano G I, Jonasson L, Haggqvist B, Einarsson E, Westermark P. Apolipoprotein A-I-derived amyloid in atherosclerosis. Its association with plasma levels of apolipoprotein A-I and cholesterol. Am J Clin Pathol 2001; 115: 298–303
   PubMed Web of Science ®Google Scholar
• Johnson K H, Sletten K, Hayden D W, O'Brien T D, Roertgen K E, Westermark P. Pulmonary vascular amyloidosis in aged dogs. A new form of spontaneously occurring amyloidosis derived from apolipoprotein A-I. Am J Pathol 1992; 141: 1013–1019
   PubMed Web of Science ®Google Scholar
• Rader D J, Gregg R E, Meng M S, Schaefer J R, Zech L A, Benson M D, Brewer H B, Jr. In vivo metabolism of a mutant apolipoprotein, apoA-I Iowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res 1992; 33: 755–763
   PubMed Web of Science ®Google Scholar
• Genschel J, Haas R, Propsting M J, Schmidt H H. Apolipoprotein A-I induced amyloidosis. FEBS Lett 1998; 430: 145–149
   PubMed Web of Science ®Google Scholar
• Almeida M R, Gales L, Damas A M, Cardoso I, Saraiva M J. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord 2005; 5: 587–596
   Google Scholar